Medical Device and Wound Care News and Analysis Blog

Opportunities in Neuromodulation: Abbott at INS 2022

Written by Anne Staylor | 6/20/22 2:11 PM

Ryan Lakin, Abbott DVP of R&D, discusses opportunities in neuromodulation in an interview with SmartTRAK at INS 2022

Ryan Lakin, Abbott’s divisional vice president of research and development, discusses Abbott’s opportunities and challenges in neuromodulation, advancing the NeuroSphere Virtual Platform outside the US, the growth and impact of remote programming and new and emerging products in an interview with SmartTRAK at the International Neuromodulation Society (INS) 2022 World Congress held in Barcelona, Spain May 21-26. 

To find out more, including what was new for Abbott at INS, opportunities in expanded indications and potential areas of product development, click on the video interview recorded live at INS 2022 (27:50 min). A link to download a complete transcript of the interview is also provided below.

Hi, this is Anne Staylor. I'm here in Barcelona at the International Neuromodulation Society meeting, and I have the pleasure of talking with Ryan Lakin, divisional Vice President of research and development for Abbott. Ryan, thank you for talking with me today.

Ryan Lakin: Happy to talk to you today, Anne. Thank you.

So, this has been a great meeting so far. What is the big news for Abbott at this INS meeting?

RL:
 For Abbott, we continue to really focus on our connected care platform through NeuroSphere. And I think that has been something that's been extremely important over the last few years through COVID, but I think specifically being at INS, being the International Neuromodulation Society, that for us to be taking NeuroSphere outside the United States and really expanding into countries outside the United States, for us is one of the biggest opportunities, especially when you think about the chronic pain space, as well as our deep brain stimulation products. For us, that's really allowing Virtual Clinic to be utilized by folks outside of just the US, where we initially launched in the beginning of 2021. We've really been expanding that globally. And for us at INS, that's really the opportunity we have and the opportunity for us to serve more patients.

What is your reach currently? What countries are you in and what are your plans for expansion?

RL: 
Today, we're in about 11 countries around the world. Initially, when we got outside the US, we initially went into Australia, went to the UK, Germany and now are expanding into the Nordics as well as into other elements of Western Europe and eventually into Canada. So we're kind of moving in pieces. And so you'll see Virtual Clinic kind of coming through a group of about another five countries in the next few months since we continually do that. Today, there's been over 10,000 people that have benefited from Virtual Clinic since...

To download a complete transcript of the interview with Abbott's Ryan Lakin at INS 2022, just click the button below.

SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK, just click here.